11 results match your criteria: "and the Corporal Michael J. Crescenz VA Medical Center[Affiliation]"
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
N Engl J Med
March 2022
From the Oklahoma Medical Research Foundation, Oklahoma City (J.T.M.); the University of Pennsylvania and the Corporal Michael J. Crescenz VA Medical Center - both in Philadelphia (V.P.W.); Northwell Health, Great Neck, NY (R.F.); Amsterdam University Medical Centers, Amsterdam (R.V.); Charité-Universitätsmedizin, Berlin (T.D.); the Military Medical Academy, Belgrade, Serbia (M.P.); Instituto Centro de Enfermedades Reumáticas, Buenos Aires (J.V.); Independent Public Clinical Hospital Number 4, Medical University of Lublin, Lublin, Poland (M.M.); Centro de Investigación y Tratamiento Reumatológico, Mexico City, Mexico (F.I.-P.); and Bristol Myers Squibb, Princeton, NJ (M.W., S.K., Y.Y., A.G., P.H.S., Z.L., N.A., N.D.).
Article Synopsis
- Iberdomide is being tested as a treatment for systemic lupus erythematosus (SLE) by promoting the degradation of key transcription factors related to immune response.
- In a phase 2 trial, 288 patients were randomly assigned to receive iberdomide in different doses or a placebo for 24 weeks, evaluating the effectiveness through a specific index called SLE Responder Index (SRI-4).
- Results showed that 54% of patients taking the highest dose of iberdomide achieved a significant clinical response compared to 35% in the placebo group, though side effects mainly included infections and low white blood cell counts.
An Unnecessary Gift for COVID-19 Vaccines and Therapeutics: The Medical Countermeasure Priority Review Voucher.
Am J Public Health
November 2021
Reshma Ramachandran is with the National Clinician Scholars Program, Yale School of Medicine, New Haven, CT, and the Veterans Affairs Connecticut Healthcare System, West Haven, CT. Ravi Gupta is with the National Clinician Scholars Program, University of Pennsylvania, Philadelphia, and the Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA. Jing Luo is with the Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Incentives for Immunity - Strategies for Increasing Covid-19 Vaccine Uptake.
N Engl J Med
July 2021
From the Perelman School of Medicine (K.G.V., C.C.C.), the Wharton School (K.G.V.), and the Center for Health Incentives and Behavioral Economics (K.G.V., C.C.C.), University of Pennsylvania; and the Corporal Michael J. Crescenz VA Medical Center (K.G.V.) - both in Philadelphia.
Improving Depression Outcome by Patient-Centered Medical Management.
Focus (Am Psychiatr Publ)
April 2020
Duke-National University of Singapore Graduate Medical School, Singapore; the Department of Psychiatry, Duke University Medical School, Durham, N.C.; the Department of Psychiatry, Texas Tech Health Sciences Center-Permian Basin, Midland-Odessa; the Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia; and the Corporal Michael J. Crescenz VA Medical Center, Philadelphia.
(Reprinted with permission from 2018; 175:1187-1198).
View Article and Find Full Text PDFBridging Polarization in Medicine - From Biology to Social Causes.
N Engl J Med
March 2020
From the Department of Medicine, Massachusetts General Hospital, and Harvard Medical School - both in Boston (K.A.); and the University of Pennsylvania and the Corporal Michael J. Crescenz VA Medical Center - both in Philadelphia (D.A.A.).
A Prospective Randomized Comparative Study of Three Guided Bronchoscopic Approaches for Investigating Pulmonary Nodules: The PRECISION-1 Study.
Chest
March 2020
Division of Pulmonary and Critical Care, University of Pennsylvania School of Medicine, Philadelphia, PA; Division of Pulmonary and Critical Care, University of Pennsylvania School of Medicine, and the Corporal Michael J. Crescenz VA Medical Center Philadelphia, PA.
Background: The capability of bronchoscopy in the diagnosis of peripheral pulmonary nodules (PPNs) remains limited. Despite decades of effort, evidence suggests that the diagnostic accuracy for electromagnetic navigational bronchoscopy (EMN) and radial endobronchial ultrasound (EBUS) approach only 50%. New developments in robotic bronchoscopy (RB) may offer improvements in the assessment of PPNs.
View Article and Find Full Text PDFWorking Safely with Vaccinia Virus: Laboratory Technique and Review of Published Cases of Accidental Laboratory Infections with Poxviruses.
Methods Mol Biol
March 2020
Division of Infectious Diseases, Perelman School of Medicine at the University of Pennsylvania and the Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA.
Vaccinia virus, the prototype Orthopoxvirus, is widely used in the laboratory as a model system to study various aspects of viral biology and virus-host interactions, as a protein expression system, as a vaccine vector, and as an oncolytic agent. The ubiquitous use of vaccinia viruses in laboratories around the world raises certain safety concerns because the virus can be a pathogen in individuals with immunological and dermatological abnormalities, and on occasion can cause serious problems in normal hosts. This chapter reviews standard operating procedures when working with vaccinia virus and reviews published cases of accidental laboratory infections with poxviruses.
View Article and Find Full Text PDFGrave Concerns Expressed by Psychiatrists Over Current Immigration Policies.
J Am Acad Child Adolesc Psychiatry
January 2019
University of Pennsylvania, Philadelphia, and the Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA.
As members of the Global Mental Health and Psychiatry Caucus of the American Psychiatric Association (APA), we would like to express our grave concerns about the ongoing policies and treatment of asylum seekers, refugees, and immigrants coming to the United States, and the adverse mental health sequelae that such policies will have on these individuals and populations.
View Article and Find Full Text PDFImproving Depression Outcome by Patient-Centered Medical Management.
Am J Psychiatry
December 2018
From the Duke-National University of Singapore Graduate Medical School, Singapore; the Department of Psychiatry, Duke University Medical School, Durham, N.C.; the Department of Psychiatry, Texas Tech Health Sciences Center-Permian Basin, Midland-Odessa; the Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia; and the Corporal Michael J. Crescenz VA Medical Center, Philadelphia.
Specific challenges that profoundly affect the outcome of treatment for depression include 1) patient engagement and retention in care and optimization of treatment adherence, 2) optimization of symptom and side effect control by medication adjustments using measurement-based care procedures, 3) restoration of daily functioning and quality of life, and 4) prevention or at least mitigation of symptomatic relapse or recurrence. According to data from the Sequenced Treatment Alternatives to Relieve Depression study, some 10%-15% of patients will not return for treatment after an initial thorough evaluation visit; an additional 20%-35% will not complete the first acute-phase treatment step, and another 20%-50% will not complete 6 months of continuation treatment. Among patients who stay in treatment, over 50% exhibit poor adherence.
View Article and Find Full Text PDFMedicaid's Path to Value-Based Reform.
N Engl J Med
July 2018
From the Department of Medicine, University of Washington, and the Value and Systems Science Lab, University of Washington Medicine Center for Scholarship in Patient Care Quality and Safety - both in Seattle (J.M.L.); the Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, and the Department of Medicine, Brigham and Women's Hospital - both in Boston (B.D.S.); and the Leonard Davis Institute of Health Economics, Wharton School, University of Pennsylvania (J.M.L., A.S.N.), and the Corporal Michael J. Crescenz VA Medical Center and the Department of Medical Ethics and Health Policy, University of Pennsylvania (A.S.N.) - all in Philadelphia.
GERI-BD: A Randomized Double-Blind Controlled Trial of Lithium and Divalproex in the Treatment of Mania in Older Patients With Bipolar Disorder.
Am J Psychiatry
November 2017
From the Department of Psychiatry and the Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, and New York Presbyterian Hospital, New York; the Department of Psychiatry, University of Toronto, and the Centre for Addiction and Mental Health, Toronto; the Department of Psychiatry, University of Pittsburgh, Pittsburgh; the Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland; the Department of Psychiatry, Louis Stokes Cleveland VA Medical Center, Cleveland; the Department of Psychiatry, University of Pennsylvania, Philadelphia, and the Corporal Michael J. Crescenz VA Medical Center, Philadelphia; the Department of Psychiatry, Baylor College of Medicine, and the Michael E. DeBakey VA Medical Center, Houston; the Department of Psychiatry, Duke University Medical College, Durham, N.C.; and NIMH, Bethesda, Md.
Objective: Clinicians treating older patients with bipolar disorder with mood stabilizers need evidence from age-specific randomized controlled trials. The authors describe findings from a first such study of late-life mania.
Method: The authors compared the tolerability and efficacy of lithium carbonate and divalproex in 224 inpatients and outpatients age 60 or older with bipolar I disorder who presented with a manic, hypomanic, or mixed episode.